Kamada (NASDAQ:KMDA) Stock Breaks Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Kamada shares moved above their 200-day moving average, trading as high as $8.14 and last at $8.10, compared with the average of $8.00.
• The company raised its 2026 revenue outlook to $205 million–$208 million and expects double-digit revenue and profit growth in 2027. Its third-quarter EPS beat estimates, though revenue came in slightly below expectations.
• Kamada declared a special $0.14-per-share dividend, and analysts maintain a consensus “Buy” rating with an average price target of $13.75.

Shares of Kamada Ltd. (NASDAQ:KMDA - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.00 and traded as high as $8.14. Kamada shares last traded at $8.10, with a volume of 206,789 shares trading hands.

Key Stories Impacting Kamada

Here are the key news stories impacting Kamada this week:

• Positive Sentiment: Kamada raised its 2026 revenue guidance to $205 million–$208 million and said it expects double-digit revenue and profitability growth in 2027. The company also reported record-high results for the first nine months of 2026. Company results and outlook
• Positive Sentiment: A three-year, $50 million U.S. source-plasma supply agreement adds a significant contract and supports growth prospects. Plasma supply deal
• Positive Sentiment: Third-quarter earnings were $0.14 per share, topping the $0.13 consensus and rising from $0.09 a year earlier. Stifel also raised its price target to $12. Earnings beat Stifel price target
• Positive Sentiment: The company declared a special cash dividend of $0.14 per share, offering a near-term shareholder return. Shareholders of record November 19 are scheduled to be paid December 9. Dividend announcement
• Negative Sentiment: Third-quarter revenue was $52.03 million, slightly below analysts’ $52.51 million estimate, limiting the strength of the earnings beat.

Wall Street Analyst Weigh In

KMDA has been the subject of a number of analyst reports. Weiss Ratings cut shares of Kamada from a "buy (b)" rating to a "buy (b-)" rating in a report on Monday. UBS Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of Kamada in a research note on Friday, September 18th. Benchmark reiterated a "buy" rating on shares of Kamada in a report on Tuesday, July 21st. Stifel Nicolaus set a $12.00 price target on shares of Kamada in a research report on Monday. Finally, Wall Street Zen raised shares of Kamada from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $13.75.

Kamada Price Performance

The company has a market capitalization of $465.83 million, a price-to-earnings ratio of 18.84, a PEG ratio of 0.64 and a beta of 0.90. The firm has a 50-day moving average price of $8.06 and a two-hundred day moving average price of $8.00.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its earnings results on Monday, November 9th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.01. The business had revenue of $52.03 million for the quarter, compared to analyst estimates of $52.51 million. Kamada had a return on equity of 9.38% and a net margin of 12.67%. On average, equities analysts predict that Kamada Ltd. will post 0.48 EPS for the current year.

Kamada Announces Dividend

The firm also recently announced a special dividend, which will be paid on Wednesday, December 9th. Investors of record on Thursday, November 19th will be given a $0.14 dividend. The ex-dividend date of this dividend is Thursday, November 19th. Kamada's dividend payout ratio (DPR) is 34.21%.

Institutional Investors Weigh In On Kamada

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kamada during the 3rd quarter worth about $25,000. China Universal Asset Management Co. Ltd. raised its position in shares of Kamada by 14.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,527 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 1,346 shares during the period. Finally, Aristides Capital LLC raised its holdings in Kamada by 4.5% in the 1st quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company's stock valued at $288,000 after acquiring an additional 1,476 shares during the period. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions. Kamada's portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.